Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Down 71.4% in January

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,200 shares, a decrease of 71.4% from the December 31st total of 4,200 shares. Based on an average trading volume of 11,400 shares, the days-to-cover ratio is presently 0.1 days.

Scinai Immunotherapeutics Stock Up 1.1 %

NASDAQ SCNI traded up $0.04 on Tuesday, reaching $3.57. The company had a trading volume of 279 shares, compared to its average volume of 8,434. The firm has a market capitalization of $3.03 million, a PE ratio of -0.01 and a beta of 2.34. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $8.92. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $3.64. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.16 and a quick ratio of 1.16.

Scinai Immunotherapeutics (NASDAQ:SCNI) last released its quarterly earnings results on Friday, November 22nd. The company reported $8.40 earnings per share for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.